Recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment NCT06589804 Conditions Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +38 more Locations University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States Fremont - Rideout Cancer Center — Marysville, California, United States VA Palo Alto Health Care System — Palo Alto, California, United States UCHealth Memorial Hospital Central — Colorado Springs, Colorado, United States View all 192 locations View more locations Show fewer locations Loading locations... View Trial Details
